Clinical Trials

A Phase I Study of MORAb-004 in Patients with Solid Tumors

Protocol
10-012
Full Title
A Study of the Safety, Tolerability, and Pharmacokinetics of MORAb-004, a Humanized Monoclonal Antibody, in Subjects with Solid Tumors
Purpose

The purpose of this study is to determine if an investigational drug called MORAb-004 is safe, how it is used by the body, and what dose should be used in future studies. MORAb-004 is a new drug that stops the formation of blood vessels that tumors need to grow.

Laboratory studies have shown that MORAb-004 made tumors smaller without causing any side effects. In this study, it will be evaluated in patients with solid tumors that persist despite prior treatment.

Investigator
Pictured: Richard Carvajal
Richard D. Carvajal - Physician Profile
Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have a solid tumor that persists despite prior therapy.
  • At least 3 weeks must have passed since completion of prior therapies and entry into the study, and patients must have recovered from any side effects.
  • Patients must be age 18 or older.

For more information and to inquire about eligibility for this study, please contact Dr. Richard D. Carvajal at 646-888-4164.

Locations
ClinicalTrials.gov